PDCD1 and paraneoplastic neurologic syndrome: Of note, studies had indicated that the presence of paraneoplastic neural antibodies prior to ICI treatment was a risk factor for the development of PNS, with existing paraneoplastic neuropathy deteriorating after PD-1/PD-L1 inhibitor treatment (36, 37).